Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment

Vascular Pharmacology

Volumn 62, Issue 2, 2014, Pages 94-102

  Werner, Christian ^a   Hoffmann, Michael M ^b   Winkler, Karl ^b   Böhm, Michael ^a   Laufs, Ulrich ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Coronary artery disease; PCSK9; Risk prediction; Statins; Triglycerides

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; PCSK9 PROTEIN, HUMAN;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CORONARY ARTERY DISEASE; FEMALE; GENDER; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; RISK;

AGED; C-REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN; MALE; MIDDLE AGED; PROPROTEIN CONVERTASES; PROSPECTIVE STUDIES; RISK; SERINE ENDOPEPTIDASES;

EID: 84905012766     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2014.03.004     Document Type: Article

References (40)

1. Abifadel M., Varret M., Rabes J.P., Allard D., Ouguerram K., Devillers M., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003, 34(2):154-156. [Epub 2003/05/06].
2. Artenstein A.W., Opal S.M. Proprotein convertases in health and disease. N Engl J Med 2011, 365(26):2507-2518. [Epub 2011/12/30].
3. Betteridge D.J. Cardiovascular endocrinology in 2012: PCSK9-an exciting target for reducing LDL-cholesterol levels. Nat Rev Endocrinol 2013, 9(2):76-78. [Epub 2013/01/09].
4. Cohen J.C., Boerwinkle E., Mosley T.H., Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006, 354(12):1264-1272. [Epub 2006/03/24].
5. Urban D., Pöss J., Böhm M., Laufs U. Targeting the proprotein convertase subtilisin/kexin type 9 (PCSK9) for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol 2013, 62(16):1401-1408.
6. U.S.National Institutes of Health Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) Available at:, [Accessed November 30, 2013]. http://clinicaltrials.gov/ct2/show/NCT01764633.
7. Desai N.R., Giugliano R.P., Zhou J., Kohli P., Somaratne R., Hoffman E., et al. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of NCEP-ATP III LDL-C goals among high risk patients: an analysis from the LAPLACE-TIMI 57 trial. J Am Coll Cardiol 2014, 63(5):430-433.
8. Desai N.R., Kohli P., Giugliano R.P., O'Donoghue M.L., Somaratne R., Zhou J., et al. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C assessment with proprotein convertase subtilisin kexin type 9 monoclonal antibody inhibition combined with statin therapy (LAPLACE)-thrombolysis in myocardial infarction (TIMI) 57 trial. Circulation 2013, 128(9):962-969. [Epub 2013/07/26].
9. Koren M.J., Giugliano R.P., Raal F.J., Sullivan D., Bolognese M., Langslet G., et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the open-label study of long-term evaluation against LDL-C (OSLER) randomized trial. Circulation 2014, 129(2):234-243.
10. Roth E.M., McKenney J.M., Hanotin C., Asset G., Stein E.A. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012, 367(20):1891-1900. [Epub 2012/11/02].
11. Stein E.A., Gipe D., Bergeron J., Gaudet D., Weiss R., Dufour R., et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012, 380(9836):29-36. [Epub 2012/05/29].
12. Stein E.A., Mellis S., Yancopoulos G.D., Stahl N., Logan D., Smith W.B., et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012, 366(12):1108-1118. [Epub 2012/03/23].
13. Sullivan D., Olsson A.G., Scott R., Kim J.B., Xue A., Gebski V., et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012, 308(23):2497-2506. [Epub 2012/11/07].
14. Le May C., Kourimate S., Langhi C., Chetiveaux M., Jarry A., Comera C., et al. Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler Thromb Vasc Biol 2009, 29(5):684-690. [Epub 2009/03/07].
15. Careskey H.E., Davis R.A., Alborn W.E., Troutt J.S., Cao G., Konrad R.J. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 2008, 49(2):394-398. [Epub 2007/11/24].
16. Costet P., Hoffmann M.M., Cariou B., Guyomarc'h Delasalle B., Konrad T., Winkler K. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis 2010, 212(1):246-251. [Epub 2010/07/14].
17. Welder G., Zineh I., Pacanowski M.A., Troutt J.S., Cao G., Konrad R.J. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res 2010, 51(9):2714-2721. [Epub 2010/06/08].
18. Stone N.J., Robinson J., Lichtenstein A.H., Merz C.N., Blum C.B., Eckel R.H., et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 2013, 2013. [Epub 2013/11/14].
19. Boekholdt S.M., Arsenault B.J., Mora S., Pedersen T.R., LaRosa J.C., Nestel P.J., et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012, 307(12):1302-1309. [Epub 2012/03/29].
20. Mora S., Glynn R.J., Boekholdt S.M., Nordestgaard B.G., Kastelein J.J., Ridker P.M. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). J Am Coll Cardiol 2012, 59(17):1521-1528. [Epub 2012/04/21].
21. Mora S., Wenger N.K., Demicco D.A., Breazna A., Boekholdt S.M., Arsenault B.J., et al. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the treating to new targets (TNT) study. Circulation 2012, 125(16):1979-1987. Epub 2012/03/31.
22. American Diabetes Association Executive summary: standards of medical care in diabetes-2011. Diabetes Care 2011, 34(Suppl. 1):S4-S10. [Epub 2011/01/14].
23. Alberti K.G., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I., Donato K.A., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120(16):1640-1645. [Epub 2009/10/07].
24. World Health Organization Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000, 894(i-xii):1-253. [Epub 2001/03/10].
25. Thygesen K., Alpert J.S., White H.D., Joint ESCAAHAWHFTFftRoMI, Jaffe A.S., Apple F.S., et al. Universal definition of myocardial infarction. Circulation 2007, 116(22):2634-2653. [Epub 2007/10/24].
26. Anderson J.L., Adams C.D., Antman E.M., Bridges C.R., Califf R.M., Casey D.E., et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2013, 61(23):e179-e347. [Epub 2013/05/04].
27. Werner N., Kosiol S., Schiegl T., Ahlers P., Walenta K., Link A., et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005, 353(10):999-1007. [Epub 2005/09/09].
28. Park S.W., Moon Y.A., Horton J.D. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem 2004, 279(48):50630-50638. [Epub 2004/09/24].
29. Ason B., Tep S., Davis H.R., Xu Y., Tetzloff G., Galinski B., et al. Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9. J Lipid Res 2011, 52(4):679-687. [Epub 2011/01/26].
30. Roubtsova A., Munkonda M.N., Awan Z., Marcinkiewicz J., Chamberland A., Lazure C., et al. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol 2011, 31(4):785-791. [Epub 2011/01/29].
31. Sun H., Samarghandi A., Zhang N., Yao Z., Xiong M., Teng B.B. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor. Arterioscler Thromb Vasc Biol 2012, 32(7):1585-1595. [Epub 2012/05/15].
32. Huijgen R., Boekholdt S.M., Arsenault B.J., Bao W., Davaine J.M., Tabet F., et al. Plasma PCSK9 levels and clinical outcomes in the TNT (treating to new targets) trial: a nested case-control study. J Am Coll Cardiol 2012, 59(20):1778-1784. [Epub 2012/05/12].
33. Akram O.N., Bernier A., Petrides F., Wong G., Lambert G. Beyond LDL cholesterol, a new role for PCSK9. Arterioscler Thromb Vasc Biol 2010, 30(7):1279-1281. [Epub 2010/06/18].
34. Soutar A.K. Unexpected roles for PCSK9 in lipid metabolism. Curr Opin Lipidol 2011, 22(3):192-196. [Epub 2011/04/16].
35. Lambert G., Sjouke B., Choque B., Kastelein J.J., Hovingh G.K. The PCSK9 decade. J Lipid Res 2012, 53(12):2515-2524. [Epub 2012/07/20].
36. Baass A., Dubuc G., Tremblay M., Delvin E.E., O'Loughlin J., Levy E., et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem 2009, 55(9):1637-1645. [Epub 2009/07/25].
37. Cui Q., Ju X., Yang T., Zhang M., Tang W., Chen Q., et al. Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. Atherosclerosis 2010, 213(2):632-636. [Epub 2010/11/03].
38. Lakoski S.G., Lagace T.A., Cohen J.C., Horton J.D., Hobbs H.H. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009, 94(7):2537-2543. [Epub 2009/04/09].
39. Chan D.C., Hamilton S.J., Rye K.A., Chew G.T., Jenkins A.J., Lambert G., et al. Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients. Diabetes Obes Metab 2010, 12(9):752-756. [Epub 2010/07/24].
40. Mbikay M., Sirois F., Mayne J., Wang G.S., Chen A., Dewpura T., et al. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett 2010, 584(4):701-706. [Epub 2009/12/23].